Tucatinib: Mechanism of Action, Dosing, and Side Effects
Tucatinib is a highly selective oral HER2 tyrosine kinase inhibitor that, when combined with trastuzumab and capecitabine, provides significant survival benefits in HER2-positive metastatic breast cancer, particularly excelling in patients with brain metastases.
Mechanism of Action
Tucatinib is a tyrosine kinase inhibitor that selectively targets HER2 1. The drug works by:
- Inhibiting phosphorylation of HER2 and HER3, which blocks downstream MAPK and AKT signaling pathways
- Suppressing cell proliferation in HER2-expressing tumor cells
- Demonstrating enhanced anti-tumor activity when combined with trastuzumab compared to either agent alone, both in vitro and in vivo 1
A critical feature is that tucatinib achieves cerebrospinal fluid concentrations comparable to unbound plasma concentrations at steady-state, explaining its exceptional intracranial efficacy 1.
Recommended Dosing
Standard dose: 300 mg orally twice daily (approximately 12 hours apart), taken with or without food 1.
Dosing Algorithm:
- Take continuously in combination with trastuzumab and capecitabine
- Swallow tablets whole—do not chew, crush, or split
- If a dose is missed or vomiting occurs, skip that dose and take the next scheduled dose at the regular time (do not double up)
- Time to steady state: approximately 4 days 1
Dose Modifications:
For severe hepatic impairment (Child-Pugh C): Reduce dose 1
For renal impairment:
- Mild to moderate (CrCl 30-89 mL/min): No adjustment needed
- Severe (CrCl <30 mL/min): Not recommended due to capecitabine contraindication 1
Storage Requirements:
- Discard unused tablets 3 months after opening the bottle 1
- Store at room temperature (68-77°F)
- Keep in original container with desiccant
Clinical Positioning
ASCO 2022 guidelines provide a strong recommendation (moderate evidence quality) for tucatinib plus trastuzumab and capecitabine as third-line therapy 2. The regimen demonstrated:
- 4.5-month overall survival gain
- 2.2-month progression-free survival gain
- Particular benefit in CNS metastases, including untreated progressing brain metastases 2
The HER2CLIMB trial showed median overall survival of 21.9 months versus 17.4 months with placebo, and among patients with brain metastases, 1-year PFS was 24.9% versus 0% 3.
Side Effects
Most Common Adverse Events (from FDA label and clinical trials):
In combination with trastuzumab and capecitabine 1:
- Diarrhea (67-73%) - Most frequent AE
- Palmar-plantar erythrodysesthesia (hand-foot syndrome) (44%)
- Nausea (33-60%)
- Elevated liver enzymes (ALT 28%, AST 26%)
- Vomiting (38%)
- Mouth sores/stomatitis
- Decreased appetite
- Anemia
- Fatigue (38%)
- Rash
Grade ≥3 Adverse Events:
- Diarrhea: 6-7%
- Elevated ALT: 13.5%
- Elevated AST: 7.1%
- Palmar-plantar erythrodysesthesia: 7%
- Fatigue: 8% 4, 3, 5
Serious Adverse Events Requiring Monitoring:
1. Diarrhea 1:
- Can be severe and lead to dehydration, hypotension, kidney problems, and death
- Requires proactive antidiarrheal management
- Monitor closely and treat aggressively
2. Hepatotoxicity 1:
- Mandatory liver function monitoring: Before treatment initiation and every 3 weeks during treatment
- Watch for: dark urine, jaundice, right upper quadrant pain
- May require dose modification or discontinuation
Treatment Discontinuation:
- 13.5% discontinued tucatinib due to treatment-emergent adverse events 5
- Grade 3-4 side effects were increased compared to placebo but generally manageable with dose modifications 2
Important Safety Considerations:
Contraception: Required during treatment and for 1 week after last dose (both males and females) 1
Fertility: May impair male and female fertility 1
Breastfeeding: Contraindicated during treatment and for 1 week after last dose 1
Drug interactions: Tucatinib is metabolized primarily by CYP2C8 and to a lesser extent CYP3A; inform providers of all medications 1
Common Pitfall to Avoid:
Do not assume tucatinib toxicity mirrors other HER2-targeted agents. While it shares some overlapping toxicities with capecitabine (diarrhea, hand-foot syndrome), the hepatotoxicity profile is distinct and requires dedicated monitoring every 3 weeks 6. The high selectivity for HER2 results in fewer off-target effects compared to less selective tyrosine kinase inhibitors like lapatinib.